# Transplantation of NiCord®, Umbilical Cord Blood-derived Ex Vivo Expanded Cells, in Patients With HM

> **NCT01816230** · PHASE1,PHASE2 · COMPLETED · sponsor: **Gamida Cell ltd** · enrollment: 36 (actual)

## Conditions studied

- Hematological Malignancies
- Acute Lymphoblastic Leukemia (ALL)
- Acute Myeloid Leukemia (AML)
- Myelodysplastic Syndrome (MDS)

## Interventions

- **DRUG:** NiCord®

## Key facts

- **NCT ID:** NCT01816230
- **Lead sponsor:** Gamida Cell ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-04
- **Primary completion:** 2017-06
- **Final completion:** 2018-06
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2020-10-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01816230

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01816230, "Transplantation of NiCord®, Umbilical Cord Blood-derived Ex Vivo Expanded Cells, in Patients With HM". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01816230. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*